PCOS Gets a New Name and a Radical New Explanation

One of the most common hormonal disorders in the world is getting a new name, and with it, a fundamentally new identity. In 2026, the Global Name Change Consortium formally adopted the term polyendocrine metabolic ovarian syndrome, or PMOS, to replace polycystic ovary syndrome, the label that has been attached to this condition for nearly a century. The diagnostic criteria remain unchanged, and a managed three-year transition is now under way, but the renaming signals something far more consequential than semantics. A sweeping review published in the Journal of Ovarian Research argues that the old name was never just misleading; it was conceptually wrong. What medicine has long treated as a cyst-driven ovarian disorder is, according to the authors, a systemic, lifelong condition that weaves together the nervous system, the immune system, metabolism, and the environment into a single self-reinforcing disease network.

The scale of the problem justifies the rethinking. PMOS affects between 5 and 20 percent of women of reproductive age worldwide, making it the single most common endocrine disorder in this population. Yet its consequences extend far beyond the infertility with which it is most often associated. The review catalogues a sobering list of long-term risks: type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, significant psychiatric morbidity, adverse pregnancy outcomes, endometrial pathology, and impaired sexual function. A condition once framed narrowly as a gynecological inconvenience is now understood as a whole-body metabolic disease with effects that ripple across decades of a patient’s life. Understanding why requires looking at three deeply interconnected pathogenic axes that the authors trace with the tools of systems biology.

The first axis is neuroendocrine disruption, and it begins in a tiny cluster of neurons deep in the hypothalamus. In the arcuate nucleus, neurons that co-express kisspeptin, neurokinin B, and dynorphin, known as KNDy neurons, act as the pacemaker for the gonadotropin-releasing hormone pulse generator, the master clock that governs the reproductive hormonal cascade. In PMOS, these neurons fire aberrantly, and the normal negative feedback that steroid hormones such as progesterone exert on them breaks down. The result is a GnRH pulse generator locked into a pathologically rapid cadence. That fast pulsing preferentially drives the release of luteinizing hormone over follicle-stimulating hormone, and the resulting hormonal imbalance within the ovary stimulates excess androgen production. The ovaries, in other words, are not the rogue organ; they are responding faithfully to corrupted instructions from the brain.

The second axis is immuno-metabolic dysregulation, a chronic low-grade inflammatory state that operates as an engine of disease amplification. The review describes an imbalance between regulatory T cells and pro-inflammatory Th17 cells, alongside activation of the NLRP3 inflammasome, a molecular machine that triggers potent inflammatory signaling. Crucially, this inflammation does not act alone. It engages in bidirectional amplification with insulin resistance and hyperandrogenism: inflammation worsens insulin resistance, insulin resistance drives more androgen production, elevated androgens promote visceral fat deposition, and that fat tissue secretes more inflammatory signals. This circular logic explains why PMOS patients so often experience progressive metabolic deterioration, and why treating any single node of the loop in isolation so frequently produces disappointing clinical results.

The third axis is the genetic, epigenetic, and environmental triad that sculpts each individual’s disease trajectory. Genome-wide association studies have identified susceptibility loci that predispose some women to the syndrome, but genes alone cannot explain its variable expression. The review highlights DNA methylation reprogramming and non-coding RNA networks as epigenetic layers that tune gene activity without altering the underlying sequence. Layered on top of these molecular mechanisms are environmental exposures, including endocrine-disrupting chemicals such as bisphenol A and per- and polyfluoroalkyl substances, and dysbiosis of the gut microbiome, which alters everything from inflammatory tone to bile acid signaling and the metabolism of short-chain fatty acids. Each of these factors can push the same underlying genetic predisposition toward different clinical presentations, helping to explain why PMOS looks so different from one patient to the next.

Perhaps the most provocative element of the review is its embrace of the Developmental Origins of Health and Disease paradigm, often abbreviated as DOHaD, to account for the striking tendency of PMOS to run in families. According to this framework, the intrauterine environment can leave epigenetic marks, a kind of molecular memory, on the developing fetus. A daughter exposed to elevated maternal androgens or metabolic stress in the womb may carry altered methylation patterns that prime her own hypothalamic and ovarian circuits toward the same syndrome decades later. When she becomes pregnant, her own metabolic state can then program the next generation. This intergenerational transmission loop, mediated by epigenetic memory rather than DNA sequence, offers a mechanistic explanation for why PMOS clusters in families even when no single gene variant is decisive.

The systems biology perspective also reframes the syndrome as a conversation among organs rather than a malfunction of one. The review traces multi-organ crosstalk among the hypothalamus, the ovary, adipose tissue, the liver, and the gut, showing how signals such as inflammatory cytokines, free fatty acids, gut-derived lipopolysaccharides, and extracellular vesicle-carried microRNAs travel between these tissues and coordinate the disease state. Adipose tissue is not merely a passive fat store but an active endocrine organ that feeds the inflammatory and insulin-resistance loops. The liver contributes through steatosis and altered sex hormone-binding globulin production. The gut microbiome modulates all of it through metabolites that reach the circulation. PMOS, in this view, is a network disease, and the polycystic ovarian morphology that gave the old syndrome its name is merely one visible symptom of a much wider circuit failure.

This integrated model also confronts one of the most clinically fraught questions in the field: how to diagnose the syndrome in adolescents. During normal puberty, the hypothalamic-pituitary-ovarian axis is still maturing, and features such as irregular cycles, acne, and polycystic ovarian morphology can be entirely physiological. This overlap creates a diagnostic grey zone in which early disease and normal development are difficult to distinguish, risking both missed diagnoses and premature labeling. The review gives careful attention to this problem and discusses 17-hydroxyprogesterone, a steroid precursor, as a tool for steroidogenic phenotyping and for the differential diagnosis of conditions such as non-classic congenital adrenal hyperplasia, rather than as a PMOS-specific causal biomarker. The distinction matters: the authors are careful throughout to separate mere association from experimental sufficiency and established clinical utility, and they devote a dedicated subsection to the evidential limits of their own model.

The practical payoff of this synthesis is a new map of therapeutic targets. NK3R antagonists, drugs that block the neurokinin 3 receptor on KNDy neurons, aim directly at the runaway GnRH pulse generator and have shown promise in early trials. NLRP3 inflammasome inhibitors target the inflammatory engine of the disease. Microbiome-directed interventions, including fecal microbiota transplantation and prebiotic or probiotic strategies, attempt to reset the gut’s contribution to inflammation and metabolism. And GLP-1 receptor agonists, the class of drugs already famous for obesity and diabetes, address the insulin resistance and weight gain that drive so much of the syndrome’s long-term harm. The promise of precision medicine here lies in matching the intervention to the patient’s dominant pathogenic axis, whether neuroendocrine, inflammatory, metabolic, or microbial.

The renaming of PCOS to PMOS will take time to filter into clinics, insurance codes, and public consciousness, and some patients have expressed mixed feelings about abandoning a familiar label. But the science behind the change is difficult to argue with. A syndrome that reshapes the brain’s reproductive pacemaker, rewires immune signaling, alters liver and gut metabolism, and can be transmitted across generations through epigenetic memory was never accurately described by the appearance of cysts on an ultrasound. The review’s authors do not overclaim; they explicitly distinguish what is established from what remains hypothesis. What they offer instead is a framework, one that transforms a confusing collection of symptoms into an intelligible systems-level disease, and in doing so, points toward a future in which treatment is aimed at the network rather than the ovary alone.

Subject of Research: Systems-biology mechanisms of polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome

Article Title: Polyendocrine metabolic ovarian syndrome (PMOS, formerly Polycystic Ovary Syndrome): a systems-biology perspective on neuroendocrine, immuno-metabolic and epigenetic mechanisms across the life course

Article References: He, Y., Zhang, F., Ding, H., Pan, H., Yu, B., Zhang, J., Shi, X., Zhang, T., & Zhao, G. (2026). Polyendocrine metabolic ovarian syndrome (PMOS, formerly Polycystic Ovary Syndrome): a systems-biology perspective on neuroendocrine, immuno-metabolic and epigenetic mechanisms across the life course. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02290-9

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02290-9

Keywords: PMOS, PCOS, KNDy neurons, insulin resistance, hyperandrogenism, NLRP3 inflammasome, gut microbiome, epigenetics, DOHaD, NK3R antagonists, GLP-1 receptor agonists, systems biology